**Name of Journal: *World Journal of Diabetes***

**Manuscript NO: 31311**

**Manuscript Type: Review**

**Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia**

Mbata O *et al*. Metabolic syndrome and diabetic retinopathy

**Osinakachukwu Mbata, Nada Fawzy Abo El-Magd, Azza Bahram El-Remessy**

**Osinakachukwu Mbata**, **Azza Bahram El-Remessy**, Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta, GA 30912, United States

**Osinakachukwu Mbata**, **Azza Bahram El-Remessy**, Medical College of Georgia/University of Georgia Medical Partnership, Athens 30606, Greece

**Nada Fawzy Abo El-Magd**, Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt

**Azza Bahram El-Remessy**, Augusta Biomedical Research Corporation, Charlie Norwood VA Medical Center, Research service line, Augusta, GA 30912, United States

**Author contributions:** Mbata O, Abo El-Magd NF, El-Remessy AB drafted and edited the manuscript; all authors approved final version of the manuscript.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Azza B El-Remessy, PhD, RPh, FAHA,** Augusta Biomedical Research Corporation, Charlie Norwood VA Medical Center, Downtown 6B-105, Augusta, GA 30912, United States. Azza.El-Remessy@va.gov

**Telephone:** +1-706-7330188

**Fax:** +1-706-8232268

**Received:** November 9, 2016

**Peer-review started:** November 10, 2016

**First decision:** February 17, 2017

**Revised:** March 22, 2017

**Accepted:** June 6, 2017

**Article in press:**

**Published online:**

**Abstract**

Diabetic retinopathy (DR) is the most feared ocular manifestation of diabetes. DR is characterized by progressive retinal damage that may eventually result in blindness. Clinically, this blindness is caused by progressive damage to the retinal microvasculature, which leads to ischemia, retinal swelling, and neovascularization. Retinopathy is associated with both type 1 and type 2 diabetes, with DR being the leading cause of new onset blindness in United States adults. Despite this strong association with diabetes, it must be noted that the development of retinopathy lesions is multifactorial and may occur in individuals without an established history of diabetes. Metabolic syndrome is a multifactorial condition of central obesity, hypertriglyceridemia, dyslipidemia, hypertension, fasting hyperglycemia, and insulin resistance. Although several studies examined the individual components observed in the metabolic syndrome in relation to the development of DR, there is conflicting data as to the association of the metabolic syndrome with the development of retinopathy lesions in non-diabetic subjects. This review will summarize the current literature on the evidence of the metabolic syndrome on retinopathy in subjects with and without an established history of diabetes. This review will also discuss some of the mechanisms through which metabolic syndrome can contribute to the development of retinopathy.

**Key words:** Diabetic retinopathy; Diabetes; Inflammation; Metabolic syndrome; Oxidative stress; Insulin resistance

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Metabolic syndrome is a multifactorial condition of central obesity, hypertriglyceridemia, dyslipidemia, hypertension, and fasting hyperglycemia and insulin resistance. Although several studies examined the individual components of the metabolic syndrome in relation to development of diabetic retinopathy, there is conflicting data as to the association of the metabolic syndrome with the development of retinopathy lesions in non-diabetic subjects. This review examined the current literature on the prevalence and impact of the components of the metabolic syndrome on the development of retinopathy in subjects with and without an established history of diabetes.

Mbata O, Abo El-Magd NF, El-Remessy AB. Obesity, metabolic syndrome and Diabetic Retinopathy: Beyond hyperglycemia.*World J Diabetes* 2017; In press

**INTRODUCTION**

Diabetes mellitus (DM) is a pathologic condition affecting approximately 29 million or 9% of people in the United States[1]. DM is a condition classified by metabolic disorder caused by chronic hyperglycemia that results in a number of pathologies including microvascular and macrovascular complications such as retinopathy, neuropathy, nephropathy, ischemic heart disease, cerebrovascular disease and peripheral vascular diseases[2,3]. Classically, DM has two etiologies that are classified as either type 1 or type 2. The hyperglycemia in type 1 DM is a direct result of destruction of the pancreatic beta cells; whereas, the hyperglycemia seen in type 2 DM is a result of insulin resistance and subsequent pancreatic beta cell dysfunction[4-6].

**SECONDARY DIABETES**

 DM may occur due to other endocrine disorders such as pituitary, adrenal and/or thyroid diseases (reviewed in[7]). These endocrine disorders are associated with sustained release of hormones that are antagonistic to insulin action including growth hormone, glucocorticoids, catecholamines or glucagon. Therefore, patients with acromegaly, Cushing syndrome, pheochromocytoma, primary hyperaldosteronism, hyperthyroidism, or glucagonoma are at high risk to develop secondary diabetes[8,9]. Chronic alcoholic pancreatitis can also result in secondary DM, where diabetes develops mainly due to deficiency in insulin[10]. A recent study identified incidence of slight to moderate diabetic retinopathy in 12.5% patients with acromegaly[11]. Nevertheless, there are no large or comprehensive studies on development of microvascular complication in general or diabetic retinopathy in particular in patients with secondary-DM.

***Pre-diabetic state “the metabolic syndrome”***

Although the ADA guidelines for a clinical diagnosis of type 2 diabetes require a random blood sugar greater than 200 mg/dL or fasting blood sugar greater than 125 mg/dL, current evidence suggests that the body undergoes significant metabolic changes prior to the development of frank diabetes[1,12]. These changes include the following: insulin resistance and the associated hyperinsulinemia and hyperglycemia, vascular endothelial dysfunction partially due to inappropriate release of cytokines from adipose tissue[13-15]. Clinically, the metabolic syndrome has several definitions but is generally diagnosed in individuals presenting with 3 of the criteria listed on Table 1: central obesity, hypertriglyceridemia, dyslipidemia, hypertension, and fasting hyperglycemia[15-17]. Current population studies have found that the metabolic syndrome affects a large number of individuals. One study in particular found its prevalence to be roughly 22% of adults in the United States, more significantly, an age-dependent increase in prevalence was also found[18]. Furthermore, a more recent study found that prevalence increased to roughly 34.5%[19]. Of note, the presence of the metabolic syndrome increases an individual’s risk of developing type 2 diabetes, cardiovascular disease, and all-cause mortality from cardiovascular disease[20-22].

**DEVELOPMENT OF RETINOPATHY IN SUBJECTS WITHOUT A HISTORY OF DIABETES**

Retinopathy has been defined in different studies to include microaneurysms, retinal hemorrhages, hard exudates, cotton wool spots, retinal venular abnormalities (venous beading and tortuosity), intraretinal microvascular abnormalities, and new blood vessels[23,24]. Although, hyperglycemia and hypertension are strongly associated with incident retinopathy, there are other etiologies including ocular and systemic causes. Ocular etiologies include central or branch retinal vein occlusion, retinal telangiectasia (“spider veins”), and retinal macroaneurysms[24]. Systemic causes range from the hypertension, carotid atherosclerotic disease, previous head radiotherapy, severe forms of all anemias, and other blood abnormalities such as sickle cell. Systemic diseases such as lupus, toxoplasmosis, and acquired immune deficiency syndrome have also been associated with the development of retinopathy lesions in patients with no history of diabetes[24,25]. There are several studies that examined the association of the components of metabolic syndrome with the development of retinopathy lesions in non-diabetic subjects. With this in mind, the focus of this review will primarily be the impact of metabolic syndrome on the development of retinopathy lesions in patients with established history of primary-DM or without history of diabetes. This review will also discuss some of the mechanisms through which metabolic syndrome can contribute to the development of retinopathy.

**DIABETIC RETINOPATHY**

Among the microvascular complications of diabetes, diabetic retinopathy (DR) is among the most feared one. Retinopathy has traditionally been viewed as a product of ischemic insult; however, this topic is well documented in other reviews[26,27]. DR is broadly classified into two stages: Nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). Classification is determined by the presence of neovascularization in the retina[27]. NPDR typically precedes PDR and is divided into the following stages: Mild, moderate, severe, and very severe. These stages are based on the likelihood that the retinopathy will progress to PDR. Clinically, a patient with NPDR presents with microvascular abnormalities such as microaneurysms and hemorrhage, affecting the macula and posterior retina. Vascular abnormalities, such as an increased permeability of the retinal vasculature and serum leakage, contribute to capillary loss and subsequent ischemia[27]. PDR is defined by the presence of neovascularization and is divided into the following stages: Early, high risk, and severe neovascularization[27]. In response to retinal hypoperfusion, an increase in local production of vasoproliferative factors such as vascular endothelial growth factor (VEGF)[27] and platelet-derived growth factor (PDGF)[28,29] occurs as a maladaptive protection mechanism. Increased levels of VEGF are traditionally correlated with stabilization of the transcription factor hypoxia-inducible factor-1 (HIF-1) levels under hypoxic conditions[30]. Both VEGF and PDGF are strongly associated with neovascularization via induction of new vascular development typically from optic disc or retinal vessels[31,32]. This neovascularization further compounds the damage by contributing to the development of preretinal and vitreous hemorrhage, fibrosis, potential retinal detachment, and blindness[33-35].

**CURRENT THERAPEUTICS FOR DR**

The mainstay standard of care for DR is the laser treatment, a highly effective procedure to slowdown visual loss in patients with PDR. The laser-mediated photocoagulation seals leaking blood vessels directly or by eliminating abnormal newly formed blood vessels in the periphery of the retina that is thought to be involved in VEGF production[36]. With VEGF being a common product strongly associated with the progression of DR, current pharmacologic treatment strategies have been based on its local inhibition within the retina[37]. Anti-angiogenic therapy was developed in attempt to improve vision in patients with diabetic macular edema (DME) as well as PDR. Indeed, monthly injections of ranibizumab, an anti-VEGF improved vision, reduced the risk of further vision loss. These results were observed after 2-years and were sustained for 3-years[38]. Anti-VEGF treatment improved macular edema in diabetic patients as well as when it was used in combination with panretinal photocoagulation in patients with PDR. The reported side effects of ranibizumab in "as - needed" treatment regimen over a 5-year.

**INSULIN RESISTANCE AND THE METABOLIC SYNDROME**

Researchers have proposed several mechanisms for the development of insulin resistance and the metabolic syndrome. These include: Genetic defects in proteins involved in the insulin action cascade, increased levels of visceral adiposity, free fatty acid levels (FFA), and chronic inflammation[39,40]. Insulin resistance in adipose tissue, regardless its molecular or environmental basis, causes decrease in FFA uptake by fat cells and/or increase in FFA release from fat cells. Under the insulin resistant state, there is impaired glucose handling by skeletal muscle and adipose tissue. This impaired glucose intake is a significant contributor to the hyperglycemia and associated vascular endothelial damage observed in insulin resistant individuals[41,42]. Additionally, insulin is important in the signaling for nitric oxide release from vascular endothelial cells, resulting in vasodilation and reduced vascular resistance, which reduces blood pressure[43,44]. Thus, there is a strong associations between the presence and extent of insulin resistance with hypertension due to increased vascular resistance and impaired glucose regulation[45,46].

Hypertension, affecting 29.8% of United States adults[47] represents the best known systemic condition associated with non-diabetic retinopathy. Hypertension is an established risk factor for the development of several cardiovascular complications including retinopathy, atherosclerosis, and aneurysms[48,49]. Poorly controlled systemic hypertension causes worsening of microvascular disease of the eye like DR[50]. Hypertensive retinopathy shared the pathophysiology of damaged retinal vascular endothelium similar to DR[51,52]. In contrast to the metabolic damage in DR, this vascular endothelial damage is mechanically induced by increased blood flow[53,54]. Despite the relationship between retinopathy and hypertension in patients without history of diabetes, one study, “The Hoorn,” identified retinopathy 8 of the 17 individuals without history of diabetes who developed retinopathy did not have hypertension. In addition, HbA1c level and waste to hip ratio (WHR) were risk factors in the nondiabetic individuals[23]. These finding suggest that retinal pathologies begin to develop prior to a clinical diagnosis of hypertension that eventually result in retinopathy.

**RETINOPATHY IN SUBJECTS WITH METABOLIC SYNDROME BUT NO HISTORY OF DIABETES**

In the absence of a clinical diagnosis of diabetes, associations have already been found between the metabolic syndrome and macro- or microvascular pathologies such as atherosclerosis, arteriosclerosis, and endothelial dysfunction[55,56]. Several studies examined the associations between the independent components of the metabolic syndrome with the development of retinal vascular injury, by measuring the mean retinal artery and venous caliber[31]. In this study, components of the metabolic syndrome including large waist circumference, lower HDL cholesterol levels, and higher BP were independently associated with reduced mean retinal arterial caliber in non-diabetic persons. Individuals with hypertriglyceridemia were significantly more likely to have arteriovenous nicking and later develop retinopathy[31]. These finding clearly show an association between the MS and retinal vascular dysfunction.

Following the earlier notion that dyslipidemia plays a critical role in DR, several studies examined the individual components observed in the metabolic syndrome in relation to DR[57-60]. Similar to the impact of dyslipidemia, there is conflicting data as to the association of the metabolic syndrome with the development of retinopathy lesions in non-diabetic subjects. One study of obese individuals older than the age of 40, found no significant correlation between the metabolic syndrome and retinopathy once diabetes and hypertension were controlled for[61]. Another population study found no significant association in the incidence of retinopathy and the metabolic syndrome in the non-diabetic population, but there was a significant association between hypertension and retinopathy[57].

In contrast, studies focusing on specific patient populations found differing results. A recent study in a Chinese population identified a positive correlation between the metabolic syndrome and retinopathy in the examined non-diabetic subjects[62,63]. In a study of Japanese adults, the metabolic syndrome was found to be associated with retinopathy; a larger waist circumference was associated with wider venular diameter and retinopathy lesions; a higher blood pressure level was associated with focal arteriolar narrowing, arteriovenous nicking, enhanced arteriolar wall reflex and narrower arteriolar diameter; and a higher triglyceride level was associated with enhanced arteriolar wall reflex[64]. In the Hoorn study, in the Netherlands, there was significant correlation of retinopathy with the combination of high waste-to-hip ratio (WHR), HbA1c level, and hypertension in non-diabetics and in glucose-impaired subjects, supporting a role for insulin resistance in the pathogenesis of retinopathy[23].

Interestingly, there was no significant correlation between incidence of retinopathy with serum levels of triglycerides, and total cholesterol or body mass index (BMI)[23]. Despite generalized obesity indicated by high BMI not being associated with retinopathy, a high-body-fat percentage indicated by WHR has been shown to be significantly associated with development of retinopathy in patients with type-2 diabetes[65]. Similar to the Hoorn study, the WHR was also an independent risk factor in the diabetic patients in the EURODIAB study[66]. These discrepancies speak to a number of possible factors including the inability of the BMI calculation to accurately estimate body composition[67,68] while the WHR is an indicator for central obesity and is associated with insulin resistance[69]. In addition, differences in measurement methods and quantification for incidence and/or rate of progression of retinopathy[57,70,71]. The other factor is that dysfunction of adipose tissue has been shown to increase oxidative stress and subsequent cytokine, contributing to the pathogenesis of retinopathy[72]. Given that hyperglycemia and hypertension are the strongest risk factors for the development of retinopathy lesions, and that these two conditions are contributors to the diagnosis of the metabolic syndrome, it may be beneficial to modify the clinical approach to individuals with the metabolic syndrome, namely those with hypertension and hyperglycemia coupled with obesity, calculated by WHR, in order to prevent or slow the development of hyperglycemia, hypertension, and hypertriglyceridemia, which in turn could possibly delay the onset of retinopathy lesions and visual impairment in subjects with these comorbidities.

**RETINOPATHY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE**

Although insulin resistance is a key pathogenic factor in both non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome, few studies examined the relationship between NAFLD and retinopathy in the presence or absence of diabetes. Central adiposity and visceral fat are important source of triglycerides leading to steatosis and NAFLD[73]. The prevalence increases in subjects with impaired glucose tolerance (43%) and in subjects with newly diagnosed DM[74]. The NHANES III was conducted by the Centers for Disease Control and Prevention using a nationwide probability sample of the United States non-institutionalized civilian population from 1988 to 1994. While a strong association between diabetes and retinopathy was observed, NAFLD was not associated with retinopathy in the non-diabetic population[75]. No significant relationship between NAFLD and incident retinopathy was observed in either diabetic or non-diabetic after adjusting for the confounders such as age, gender, ethnicity, and metabolic components. In addition, this same study found no significant increase in DR prevalence in individuals with both DM and NAFLD[75]. In contrast, prior studies observed a positive association between pediatric NAFLD participants and the degree of retinopathy signs[76]. Additionally, NAFLD was associated with increased rates of chronic kidney disease and proliferative diabetic retinopathy in individuals with type 2 diabetes in Italy[77]. Of note, NAFLD was not significantly correlated with the incidence of retinopathy in patients with NPDR after adjusting for multiple factors[77].

**RETINOPATHY IN PATIENTS WITH METABOLIC SYNDROME AND HISTORY OF DIABETES**

Traditionally, the development of DR in patients with type 1 or type 2 diabetics has been linked to the associated hyperglycemia[78]. Whether the existence of metabolic syndrome in these patients can accelerate or aggravate the incidence of DR is not clear. For example, the findings of the landmark studies, Land mark clinical trials including United Kingdom Prospective Diabetes Study (UKPDS) in patients with type-2 diabetes[79,80], the Diabetic Control and Complications Trial (DCCT), in patients with type-1 diabetes[81] and its follow-up, the Epidemiology of Diabetes and Interventions and Complications (EDIC)[82,83] were traditionally interpreted that tight glycemic control significantly delayed development of DR. However, the level of reduction was significantly lower in patients with type 2 diabetes (25%) and 76% in patients with type 1 diabetes, suggesting that factors outside of hyperglycemia associated with type 2 diabetes may play a role in the pathology of the microvascular complications such as retinopathy[82,83]. Also, the tight metabolic control, individually and coupled with other interventions, has been shown to significantly decrease the incidence of retinopathy, while also increasing the quality and duration of life in these patients[82]. With this population beginning to live longer, the rates and incidence of comorbid metabolic syndrome and type 1 diabetes has begun to increase as this population begins to be more representative of the general United States population[84].

Another study in patients with type 1 diabetes found that tight glycemic control had threshold effectiveness at reducing the incidence of retinopathy. When looking for other associations, they found that once the duration of hyperglycemia was controlled for, increased waist to hip ratio (WHR) and fasting triglyceride levels were the only other factors strongly associated with the incidence of retinopathy in these patients[85]. Interestingly, a study in Belgium found that patients with type-1 diabetes who are overweight and had higher BMI had more retinopathy than normal-weight diabetic patients. Patients with retinopathy were older and had a longer diabetes duration and higher A1C than individuals without retinopathy[86]. However, one study took a different approach to studying this relationship by estimating the prevalence of DR in individuals with the metabolic syndrome depending on the number of MS components these individuals had[65]. This study focused on diabetic patients but normalized for several associated parameters including HbA1C. This study found a linear relationship between the number of MS components and the prevalence of DR[65]. These findings support the relationship between the metabolic syndrome, namely the obesity and hypertriglyceridemia, and the development and/or progression of DR. Given that these conditions are strongly associated with type 2 diabetes, and are components of the metabolic syndrome, it would be logical to look into their contribution to the incidence of retinopathy in this population[87]. Other studies found positive correlations between the comorbid metabolic syndrome and type 2 diabetes with all cardiovascular complications including DR[88,89]. Furthermore, other studies found that the presence of hyperinsulinemia and dyslipidemia in type 2 diabetics was associated with the onset of microvascular complications[90,91]. A case-controlled study, with data obtained from 2551 Chinese participants found that the trend to develop DR with metabolic syndrome was significantly higher than that without metabolic syndrome. Metabolic syndrome was an independent statistical indicator of the presence of DR after adjusting for age and sex as well as HbA1c and duration of diabetes[65]. Additively these findings bolster the claim that in addition to hyperglycemia and hypertension, the hypertriglyceridemia seen in several individuals in this population may very well play a significant role in the pathogenesis of DR in this population.

**DYSLIPIDEMIA AND DEVELOPMENT OF DR**

Diabetic dyslipidemia is traditionally characterized by high plasma triglycerides and low-density lipoprotein cholesterol (LDL) and reduced levels of high density lipoprotein cholesterol (HDL). While early studies have suggested positive correlation between dyslipidemia and hard exudates, longitudinal studies in patients with type-1 diabetes found modest impact of increased total cholesterol and HDL on the incidence of DR[92]. Of note, serum triglyceride levels were not considered in that study. As discussed in the review by Sabanayagam *et al*[93] 2016, changes in the circulating levels of lipids are not always associated with DR progression. A recent meta-analysis revealed that the triglycerides, total cholesterol and LDL cholesterol were signiﬁcantly elevated in persons with diabetic macular edema (DME) when compared to those with DM without DME[94]. In the Madrid Diabetes Study, higher LDL cholesterol level increased the 4-year risk for DR by 8-fold in type 2 diabetes[95]. In contrast, higher levels of total and LDL cholesterol were found to be protective of any retinopathy in a Singapore study as well as in a multi-ethnic United States population study[96,97]. In a follow-up analysis of the DCCT-EDIC from type-1 diabetic patients, the severity of retinopathy was positively associated with triglycerides (combined cohort) and negatively associated with HDL cholesterol in men from combined cohort[98]. Advanced lipoprotein profiling identified positive association of retinopathy with small and medium VLDL and negatively with VLDL sizes. No associations were found with apolipoprotein-A1, Lipoprotein(a), or susceptibility of LDL to oxidation in type-1 diabetic patients.

The early belief that dyslipidemia plays a critical role in DR, initiated several studies that examined the impact of lipid lowering drugs on DR. As discussed in the review by Modjtahedi *et al*[99] 2016, overall there are variable results but the majority of the studies support a protective role of some lipid lowering agents such as fenofibrate in mitigating hard exudates and DR. The beneficial effects of lipid lowering agents are not fully attributed to correcting dyslipidemia and may be attributed to anti-inflammatory, antioxidants and anti-apoptotic effects. Finally, two major randomized clinical trials showed that fenofibrate, a drug that is used to reduce cholesterol significantly inhibited DR progression in diabetic patients[100,101]. Lastly, a multinational case-control study suggested that conventional serum lipids profiles are unlikely to show clear and dependent effects on the development of DR[102]. The published literature suggested an association between diabetic dyslipidemia and DR; however, a more detailed and specific subtype of lipids or lipoproteins may have a clear pathogenic role rather than traditional lipid profile. In addition, alternative hypothesis suggests that initial damage to the retina barrier facilitate leakage of lipids and its oxidized metabolite to exert local adverse effects that are not necessarily mirrored by significant alteration in serum lipid profile[99].

**MECHANISMS ASSOCIATED WITH RETINOPATHY IN THE METABOLIC SYNDROME**

DR is classically perceived as microvascular disease with initial vascular endothelial damage as a direct result of hyperglycemia. Given the known pathophysiology of the components of the metabolic syndrome, as well as its association with type 2 diabetes[46,103], we will discuss the common major mechanisms of pathology in both the metabolic syndrome and diabetes.

For retinopathy in patients with an established history of diabetes, hyperglycemia has been identified as primary factor evident by the strong correlation between an individual’s HbA1c and the development of DR[79]. Results from the clinical trial UKPDS in patients with type-2 diabetes[79,80] and the DCCT in patients with type-1 diabetes[81] established that intensive glycemic control significantly reduced the incidence of retinopathy. More specifically, risk reduction of DR was found to be 76% in patients with type-1 diabetes and 25% in type-2 diabetics. Several studies examined mechanisms involved in hyperglycemic damage include non-enzymatic glycosylation of vascular basement membrane, advanced glycation end products and osmotic damage due to the conversion of circulating sugars to sorbitol by aldose reductase[78,104,105]. Studies have found that diabetes mellitus and the metabolic syndrome both, increase reactive oxygen species (ROS) production and decrease the antioxidant capacity. This is associated with oxidative damage of cell components such as proteins, lipids, and nucleic acids can trigger a chronic inflammatory response[106,107]. Impact and sources of hyperglycemia-derived oxidative stress and proinflammatory cytokines in the diabetic retina are well-documented in the literature[108,109]. As depicted in Figure 1, the aforementioned mechanisms result in vascular endothelial cell dysfunction and an increase in local immune cell activity resulting in a leukocyte oxidative burst and the associated increased leukostasis, vascular permeability[110,111]. Inflammation-mediated leukostasis has been linked to pericyte and endothelial cell death, retinal ischemia, and neovascularization, which contribute to vision loss in DR[109].

In contrast, identifying mechanisms involved in retinopathy associated with the metabolic syndrome is not a straightforward task. The metabolic syndrome is a combination of several criteria (Table 1) including central obesity, hypertriglyceridemia, insulin resistance, dyslipidemia, hypertension, and fasting hyperglycemia. Furthermore, central obesity and the excess adipose tissue observed in obese individuals partially contribute to the development of the insulin resistance syndrome and cardiovascular disease. As depicted in Figure 2, metabolic syndrome and endocrine dysfunction of adipose tissue can be very important in the development of retinopathy lesions and progression of the DR.

**ADIPOSE TISSUE DYSFUNCTION AND ADIPOKINES**

In healthy adults, adipose tissue secretes a number of factors such as resistin and pro-inflammatory cytokines such as TNFα and IL-6, which participate in the activation of macrophages that further perpetuate this inflammatory cascade. When adipose tissue is accumulated, as it is in obesity due to increased adipose tissue, it begins to operate in a dysfunctional manner. Additionally, in the obese state, adipose tissue secretes reduced amounts of the anti-inflammatory adipokine adiponectin, an adipokine that normally acts to increase insulin sensitivity by inhibiting hepatic gluconeogenesis and augmenting skeletal muscle glucose uptake[14,112]**.** In addition to these factors, it appears that excess adipose tissue leads to dysfunctional release of several other factors including retinol binding protein-1 and leptin[14,9]. The abnormal release of these factors contribute to insulin resistance by further dysregulating glucose homeostasis and augmenting hyperphagia and hyperglycemia induced damage[14].

Recently, the endocrine function of adipose tissue has become the focus of several studies. These functions include the secretion of adiponectin and resistin, both of which are involved in insulin sensitization, and subsequent increased glucose uptake[14,113]. Adiponectin functions to increase insulin sensitivity and is secreted at high levels in lean individuals with low levels of adipose tissue. However, as adipose tissue increases, the level of adiponectin secreted by adipose tissue decreases partially due to the increased secretion of pro-inflammatory markers and their associated induction of oxidative stress[14,113,114]. Another significant adipokine, resistin, is abnormally increased in obese individuals and is a contributor to the development and progression of the insulin resistance[14,115,116]. Dysfunctions in these processes, independent of causing direct damage to vascular endothelium, can contribute to insulin resistance and hyperglycemia. One study looking at the progression from non-proliferative to proliferative, found a strong association between the progression of retinopathy and increased c-reactive protein levels and increased serum resistin, a protein secreted by several tissues including white adipose tissue, nonfat cells of adipose tissue, bone marrow, and lung. This study found that increased serum resistin was associated with obesity and was highest in obese individuals with diabetes. Furthermore, increased serum resistin was associated with increased triglycerides and the progression of retinopathy[117,118]. These findings further bolster the association between DR and hypertriglyceridemia particularly due to resistin’s association with obesity and increased triglycerides. Furthermore, resistin’s association with retinopathy is made more plausible given its association with type 2 DM, insulin resistance, and inflammation. All of these factors have demonstrated associations with DR; however, the specific role of resistin in inflammation has not yet been elucidated[117,119]. Given that c-reactive protein is a known inflammatory biomarker related to vascular endothelial dysfunction and atherogenesis, its association with increased serum resistin levels provides additional support for adipose tissue dysfunction in the obese state contributing to the pathologies associated with diabetes including DR[117,118].

**ADIPOSE TISSUE AND FFA**

Adipose tissue can contribute to insulin resistance by regulating the level of the FFAs or the non-esterified fatty acids (NEFAs) depending on the body’s energy status[120,121]. Circulating NEFAs/FFAs reduce adipocyte and muscle glucose uptake, and also promote hepatic glucose output. Because lipolysis in adipocytes is depressed by insulin, insulin resistance from any cause can lead to NEFA elevation, which, in turn, induces additional insulin resistance as part of a vicious cycle that eventually contribute to diabetic complication including DR[120,121]. Furthermore, a prior study found that a long-acting antilipolytic drug could lower FFA levels in 9-lean control subjects, 13-obese nondiabetic subjects, 10-obese subjects with impaired glucose tolerance, and 11 patients with type 2 diabetes[122]. The results showed FFA lowering drugs improved oral glucose tolerance in both lean and obese nondiabetic subjects and in obese patients with type 2 diabetes, supporting the notion that adipose tissue can contribute to the pathologies associated with insulin resistance[122].

**INFLAMMATION**

The involvement of the inflammatory pathway in retinopathy associated with metabolic syndrome is critical in the light of the observation that obesity, hypertension, hyperlipidemias, and insulin resistance are considered low-grade systemic inflammatory conditions[123]. A major contributor to this inflammation is the release of pro-inflammatory cytokines by immune cells such as macrophages, lymphocytes, and leukocytes after they infiltrate the adipose tissue[14,124,125]. The pro-inflammatory cytokines secreted by adipose tissue include interleukins, notably IL-1beta, IL-6, and tumor necrosis factor alpha[126]. These cytokines contribute to the impairment of glucose homeostasis, insulin signaling and development of insulin resistance and cardiovascular complications such as DR[127-130].

The retina is rich in n-3 polyunsaturated fatty acids (PUFAs) and upon activation of phospholipase A2, release of the metabolites arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in response to various stimuli including growth factors, cytokines and free radicals[131]. The AA, EPA and DHA are metabolized by cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 (CYP450) enzymes[123]. The AA forms a precursor to pro-inflammatory prostaglandins, thromboxanes and leukotrienes in general. It is noteworthy that AA can also give rise to lipoxins, which are potent anti-inflammatory molecules. Similarly, EPA gives rise to resolvins and DHA to protectins, which possess significant anti-inflammatory properties. As such, these molecules may have a role in modulating the chronic inflammatory state observed in DR and metabolic syndrome[131].

Inflammation in DR has also been linked to induction of the cyclooxygenase-2 (COX-2) pathway. Induction of the COX-2 pathway results in a dysfunctional increase in the production of prostaglandins and thromboxane[132]. This dysfunctional production contributes to the chronic inflammatory pathologies by augmenting the vascular permeability noted in these patients, increasing platelet aggregation and leukostasis, which results in the increased local production of pro-inflammatory cytokines[32]. Furthermore, the increased products of the COX-2 pathway in the diabetic patients, has been associated with the increased local secretion of VEGF in the retina, a major contributor to the progression of DR[133,134]. Prior studies have shown that PUFAs, especially EPA and DHA, inhibit the production of both IL-6 and TNF-α and suppress the expression of VEGF[135]. Leukotrienes have been found to be increased in the retinas of diabetic mice. These inflammatory factors contribute to several of the dysfunctions noted chronic retinal inflammation including the increased vascular permeability and increased production of free radicals[131].

**CONCLUSION**

The prevalence of DM and its associated pathologies have significantly increased as a result of increasing prevalence of obesity and insulin resistance. For retinopathy in patients with established history of DM, hyperglycemia remains the most consistent risk factor for DR in type 1 diabetes across different studies and populations (Figure 1). While blood pressure is an important risk factor for DR in type 2 diabetes, correlation with serum levels of lipids are not consistent. Meanwhile, considerable evidence showed that central obesity, insulin resistance and dyslipidemia are associated with retinopathy lesion in non-diabetic and diabetic patients. As depicted in Figure 3, the cascade of events involved in development of DR is complex and interrelated and not entirely driven by hyperglycemia in patients with metabolic syndrome. Moreover, diabetic macular edema rather than PDR is the increasingly common cause of visual impairment. Patients with type 2 diabetes with dyslipidemia show higher tendency for DME and can benefit from cholesterol reducing agents such as fenfibrate in addition to antidiabetic agents. Although the current anti-VEGF therapies are beneficial in some patients with DR, about 50% of other patients do not respond adequately. This calls for additional studies to find better treatment and management strategies to prevent its currently incurable complications, such as DR, should be of high priority. Therefore, targeting components of the metabolic syndrome could be a beneficial preventative/dilatory intervention. Specifically, understanding the pathways involved in dysfunction of adipose tissue and the associated alteration of PUFA, FFA and adipokines such as adiponectin and resistin contribute to inflammation and cardiovascular complications including retinopathy lesions in both diabetics and non-diabetics. Novel strategies to suppress systemic and local inflammation seen in DR should be further explored in order to prevent and/or delay DR.

**REFERENCES**

1. Prevention CfDCa. Prediabetes: United States. Department of Health and Human Services; 2015. [accessed 2016 Jun]. Available from: URL: http: //www.cdc.gov/diabetes/basics/prediabetes.html
2. **Herman WH**. Diabetes epidemiology: guiding clinical and public health practice: the Kelly West Award Lecture, 2006. *Diabetes Care* 2007; **30**: 1912-1919 [PMID: 17496237 DOI: 10.2337/dc07-9924]
3. **Hadi HA**, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. *Vasc Health Risk Manag* 2007; **3**: 853-876 [PMID: 18200806]
4. **Mahler RJ**, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. *J Clin Endocrinol Metab* 1999; **84**: 1165-1171 [PMID: 10199747 DOI: 10.1210/jcem.84.4.5612]
5. **Van den Driessche A**, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. *Neth J Med* 2009; **67**: 376-387 [PMID: 20009114]
6. **Olokoba AB**, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. *Oman Med J* 2012; **27**: 269-273 [PMID: 23071876 DOI: 10.5001/omj.2012.68]
7. **Resmini E**, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. *Acta Diabetol* 2009; **46**: 85-95 [PMID: 19322513 DOI: 10.1007/s00592-009-0112-9]
8. **Reddy R**, Hope S, Wass J. Acromegaly. *BMJ* 2010; **341**: c4189 [PMID: 20713585 DOI: 10.1136/bmj.c4189]
9. **Arnaldi G**, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. *Pituitary* 2004; **7**: 253-256 [PMID: 16416038 DOI: 10.1007/s11102-005-1172-7]
10. **Larsen S**. Diabetes mellitus secondary to chronic pancreatitis. *Dan Med Bull* 1993; **40**: 153-162 [PMID: 8495594]
11. **Azzoug S**, Chentli F. Diabetic retinopathy in acromegaly. *Indian J Endocrinol Metab* 2014; **18**: 407-409 [PMID: 24944939 DOI: 10.4103/2230-8210.131207]
12. Classification and Diagnosis of Diabetes. *Diabetes Care* 2015: S13
13. **Ouchi N**, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. *Curr Opin Lipidol* 2003; **14**: 561-566 [PMID: 14624132 DOI: 10.1097/00041433-200312000-00003]
14. **Ouchi N**, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011; **11**: 85-97 [PMID: 21252989 DOI: 10.1038/nri2921]
15. **Kaur J**. A comprehensive review on metabolic syndrome. *Cardiol Res Pract* 2014; **2014**: 943162 [PMID: 24711954]
16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; **285**: 2486-2497 [PMID: 11368702 DOI: 10.1001/jama.285.19.2486]
17. **Miranda PJ**, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. *Am Heart J* 2005; **149**: 33-45 [PMID: 15660032 DOI: 10.1016/j.ahj.2004.07.013]
18. **Ford ES**, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. *Diabetes Care* 2004; **27**: 2444-2449 [PMID: 15451914 DOI: 10.2337/diacare.27.10.2444]
19. **Ford ES**. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. *Diabetes Care* 2005; **28**: 2745-2749 [PMID: 16249550 DOI: 10.2337/diacare.28.11.2745]
20. **Hanson RL**, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. *Diabetes* 2002; **51**: 3120-3127 [PMID: 12351457 DOI: 10.2337/diabetes.51.10.3120]
21. **Sattar N**, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, Lennon L, Macfarlane PW, Murphy MB, Packard CJ, Stott DJ, Westendorp RG, Whincup PH, Shepherd J, Wannamethee SG. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. *Lancet* 2008; **371**: 1927-1935 [PMID: 18501419 DOI: 10.1016/S0140-6736(08)60602-9]
22. **Ford ES**, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. *Diabetes Care* 2008; **31**: 1898-1904 [PMID: 18591398 DOI: 10.2337/dc08-0423]
23. **van Leiden HA**, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. *Arch Ophthalmol* 2003; **121**: 245-251 [PMID: 12583792 DOI: 10.1001/archopht.121.2.245]
24. **Venkatramani J**, Mitchell P. Ocular and systemic causes of retinopathy in patients without diabetes mellitus. *BMJ* 2004; **328**: 625-629 [PMID: 15016695 DOI: 10.1136/bmj.328.7440.625]
25. **Brown GC**, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation retinopathy. *Ophthalmology* 1982; **89**: 1494-1501 [PMID: 7162794 DOI: 10.1016/S0161-6420(82)34611-4]
26. **Antonetti DA**, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. *Diabetes* 2006; **55**: 2401-2411 [PMID: 16936187 DOI: 10.2337/db05-1635]
27. **Aiello LM**. Perspectives on diabetic retinopathy. *Am J Ophthalmol* 2003; **136**: 122-135 [PMID: 12834680 DOI: 10.1016/S0002-9394(03)00219-8]
28. **Cox OT**, Simpson DA, Stitt AW, Gardiner TA. Sources of PDGF expression in murine retina and the effect of short-term diabetes. *Mol Vis* 2003; **9**: 665-672 [PMID: 14685146]
29. **Mori K**, Gehlbach P, Ando A, Dyer G, Lipinsky E, Chaudhry AG, Hackett SF, Campochiaro PA. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. *Invest Ophthalmol Vis Sci* 2002; **43**: 2001-2006 [PMID: 12037011]
30. **Lin M**, Chen Y, Jin J, Hu Y, Zhou KK, Zhu M, Le YZ, Ge J, Johnson RS, Ma JX. Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells. *Diabetologia* 2011; **54**: 1554-1566 [PMID: 21360191 DOI: 10.1007/s00125-011-2081-0]
31. **Zhou J**, Wang S, Xia X. Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. *Curr Eye Res* 2012; **37**: 416-420 [PMID: 22409294 DOI: 10.3109/02713683.2012.661114]
32. **Schoenberger SD**, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased prostaglandin E2 (PGE2) levels in proliferative diabetic retinopathy, and correlation with VEGF and inflammatory cytokines. *Invest Ophthalmol Vis Sci* 2012; **53**: 5906-5911 [PMID: 22871833 DOI: 10.1167/iovs.12-10410]
33. **Wong-Riley MT**. Energy metabolism of the visual system. *Eye Brain* 2010; **2**: 99-116 [PMID: 23226947 DOI: 10.2147/EB.S9078]
34. **Kowluru RA**, Chan PS. Oxidative stress and diabetic retinopathy. *Exp Diabetes Res* 2007; **2007**: 43603 [PMID: 17641741]
35. Prevention CfDCa. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States Atlanta, Ga: United States. Department of Health and Human Services; 2011. [accessed 2016 Jun]. Available from: URL: https: //www.cdc.gov/diabetes/pubs/pdf/ndfs\_2011.pdf
36. **Deschler EK**, Sun JK, Silva PS. Side-effects and complications of laser treatment in diabetic retinal disease. *Semin Ophthalmol* 2014; **29**: 290-300 [PMID: 25325854 DOI: 10.3109/08820538.2014.959198]
37. **Waisbourd M**, Goldstein M, Loewenstein A. Treatment of diabetic retinopathy with anti-VEGF drugs. *Acta Ophthalmol* 2011; **89**: 203-207 [PMID: 21044274 DOI: 10.1111/j.1755-3768.2010.02010.x]
38. **Brown DM**, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, Schlottmann PG, Rundle AC, Zhang J, Rubio RG, Adamis AP, Ehrlich JS, Hopkins JJ. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. *Ophthalmology* 2013; **120**: 2013-2022 [PMID: 23706949 DOI: 10.1016/j.ophtha.2013.02.034]
39. **Sutherland JP**, McKinley B, Eckel RH. The metabolic syndrome and inflammation. *Metab Syndr Relat Disord* 2004; **2**: 82-104 [PMID: 18370640 DOI: 10.1089/met.2004.2.82]
40. **Eckel RH**, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; **365**: 1415-1428 [PMID: 15836891 DOI: 10.1016/S0140-6736(05)66378-7]
41. **Petersen KF**, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. *Proc Natl Acad Sci U S A* 2007; **104**: 12587-12594 [PMID: 17640906 DOI: 10.1073/pnas.0705408104]
42. **Muniyappa R**, Sowers JR. Role of insulin resistance in endothelial dysfunction. *Rev Endocr Metab Disord* 2013; **14**: 5-12 [PMID: 23306778 DOI: 10.1007/s11154-012-9229-1]
43. **Muniyappa R**, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. *Endocr Rev* 2007; **28**: 463-491 [PMID: 17525361 DOI: 10.1210/er.2007-0006]
44. **Vincent MA**, Clerk LH, Lindner JR, Klibanov AL, Clark MG, Rattigan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. *Diabetes* 2004; **53**: 1418-1423 [PMID: 15161743 DOI: 10.2337/diabetes.53.6.1418]
45. **Akande TO**, Adeleye JO, Kadiri S. Insulin resistance in Nigerians with essential hypertension. *Afr Health Sci* 2013; **13**: 655-660 [PMID: 24250303 DOI: 10.4314/ahs.v13i3.19 ]
46. **Rao G**. Insulin resistance syndrome. *Am Fam Physician* 2001; **63**: 1159-1163 [PMID: 11277552]
47. Prevention CfDCa. Prevalence of Hypertension and Controlled Hypertension - United States, 2007-2010. *MMWR* 2013: 144
48. **Wong TY**, Mitchell P. The eye in hypertension. *Lancet* 2007; **369**: 425-435 [PMID: 17276782 DOI: 10.1016/S0140-6736(07)60198-6]
49. **Kumar J**. Epidemiology of hypertension. *Clinical Queries: Nephrology* 2013: 56 [DOI: 10.1016/j.cqn.2013.04.005]
50. **Chatterjee S**, Chattopadhyay S, Hope-Ross M, Lip PL. Hypertension and the eye: changing perspectives. *J Hum Hypertens* 2002; **16**: 667-675 [PMID: 12420190]
51. **Klein R**, Klein BE, Moss SE, Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. *Arch Ophthalmol* 1994; **112**: 92-98 [PMID: 8285901 DOI: 10.1001/archopht.1994.01090130102026]
52. **Yu T**, Mitchell P, Berry G, Li W, Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. *Arch Ophthalmol* 1998; **116**: 83-89 [PMID: 9445212 DOI: 10.1001/archopht.116.1.83]
53. **Bhargava M**, Ikram MK, Wong TY. How does hypertension affect your eyes? *J Hum Hypertens* 2012; **26**: 71-83 [PMID: 21509040 DOI: 10.1038/jhh.2011.37]
54. **Garner A**, Ashton N. Pathogenesis of hypertensive retinopathy: a review. *J R Soc Med* 1979; **72**: 362-365 [PMID: 399635]
55. **Golden SH**, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes* 2002; **51**: 3069-3076 [PMID: 12351449 DOI: 10.2337/diabetes.51.10.3069]
56. **Duncan BB**, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. *Diabetes* 2003; **52**: 1799-1805 [PMID: 12829649 DOI: 10.2337/diabetes.52.7.1799]
57. **Keenan JD**, Fan AZ, Klein R. Retinopathy in nondiabetic persons with the metabolic syndrome: findings from the Third National Health and Nutrition Examination Survey. *Am J Ophthalmol* 2009; **147**: 934-44, 944.e1-2 [PMID: 19243735]
58. **Klein R**, Klein BE, Moss SE, Wong TY. The relationship of retinopathy in persons without diabetes to the 15-year incidence of diabetes and hypertension: Beaver Dam Eye Study. *Trans Am Ophthalmol Soc* 2006; **104**: 98-107 [PMID: 17471330]
59. **Engerman RL**. Pathogenesis of diabetic retinopathy. *Diabetes* 1989; **38**: 1203-1206 [PMID: 2676655 DOI: 10.2337/diab.38.10.1203]
60. **Klein R**, Myers CE, Lee KE, Klein BE. 15-year cumulative incidence and associated risk factors for retinopathy in nondiabetic persons. *Arch Ophthalmol* 2010; **128**: 1568-1575 [PMID: 21149781 DOI: 10.1001/archophthalmol.2010.298]
61. **Wong TY**, Duncan BB, Golden SH, Klein R, Couper DJ, Klein BE, Hubbard LD, Sharrett AR, Schmidt MI. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities study. *Invest Ophthalmol Vis Sci* 2004; **45**: 2949-2954 [PMID: 15326106 DOI: 10.1167/iovs.04-0069]
62. **Liu L**, Yue S, Wu J, Zhang J, Lian J, Teng W, Huang D, Chen L. Prevalence and risk factors of retinopathy in patients with or without metabolic syndrome: a population-based study in Shenyang. *BMJ Open* 2015; **5**: e008855 [PMID: 26667013 DOI: 10.1136/bmjopen-2015-008855]
63. **Peng XY**, Wang FH, Liang YB, Wang JJ, Sun LP, Peng Y, Friedman DS, Liew G, Wang NL, Wong TY. Retinopathy in persons without diabetes: the Handan Eye Study. *Ophthalmology* 2010; **117**: 531-517 [PMID: 20036013]
64. **Kawasaki R**, Tielsch JM, Wang JJ, Wong TY, Mitchell P, Tano Y, Tominaga M, Oizumi T, Daimon M, Kato T, Kawata S, Kayama T, Yamashita H. The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study. *Br J Ophthalmol* 2008; **92**: 161-166 [PMID: 17965107 DOI: 10.1136/bjo.2007.127449]
65. **Gao L**, Xin Z, Yuan MX, Cao X, Feng JP, Shi J, Zhu XR, Yang JK. High Prevalence of Diabetic Retinopathy in Diabetic Patients Concomitant with Metabolic Syndrome. *PLoS One* 2016; **11**: e0145293 [PMID: 26745177 DOI: 10.1371/journal.pone.0145293]
66. **Stratton IM**, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia* 2001; **44**: 156-163 [PMID: 11270671 DOI: 10.1007/s001250051594]
67. **Liu P**, Ma F, Lou H, Liu Y. The utility of fat mass index vs. body mass index and percentage of body fat in the screening of metabolic syndrome. *BMC Public Health* 2013; **13**: 629 [PMID: 23819808 DOI: 10.1186/1471-2458-13-629]
68. **Etchison WC**, Bloodgood EA, Minton CP, Thompson NJ, Collins MA, Hunter SC, Dai H. Body mass index and percentage of body fat as indicators for obesity in an adolescent athletic population. *Sports Health* 2011; **3**: 249-252 [PMID: 23016014 DOI: 10.1177/1941738111404655]
69. **Widgren BR**, Urbanavicius V, Attvall S, Persson B. Insulin sensitivity is more related to fat distribution than to heredity for hypertension in normotensive men. *Metabolism* 1994; **43**: 883-886 [PMID: 8028513 DOI: 10.1016/0026-0495(94)90271-2]
70. **Kassi E**, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. *BMC Med* 2011; **9**: 48 [PMID: 21542944 DOI: 10.1186/1741-7015-9-48]
71. **Bhargava M**, Cheung CY, Sabanayagam C, Huang L, Lamoureux EL, Wang JJ, Tai ES, Heng CK, Ikram MK, Mitchell P, Wong TY. Prevalence and risk factors for retinopathy in persons without diabetes: the Singapore Indian Eye Study. *Acta Ophthalmol* 2014; **92**: e602-e609 [PMID: 24894034 DOI: 10.1111/aos.12446]
72. **Blüher M**. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? *Clin Sci (Lond)* 2016; **130**: 1603-1614 [PMID: 27503945 DOI: 10.1042/CS20160005]
73. **Bedogni G**, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; **42**: 44-52 [PMID: 15895401 DOI: 10.1002/hep.20734]
74. **Ortiz-Lopez C**, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, Hardies J, Cusi K. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). *Diabetes Care* 2012; **35**: 873-878 [PMID: 22374640 DOI: 10.2337/dc11-1849]
75. **Lin TY**, Chen YJ, Chen WL, Peng TC. The Relationship between Nonalcoholic Fatty Liver Disease and Retinopathy in NHANES III. *PLoS One* 2016; **11**: e0165970 [PMID: 27802330 DOI: 10.1371/journal.pone.0165970]
76. **Liccardo D**, Mosca A, Petroni S, Valente P, Giordano U, Mico' AG, Pescosolido S, Buzzonetti L, Nobili V. The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). *J Gastroenterol* 2015; **50**: 903-912 [PMID: 25516385 DOI: 10.1007/s00535-014-1024-1]
77. **Targher G**, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. *Diabetologia* 2008; **51**: 444-450 [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4]
78. **Frank RN**. Diabetic retinopathy. *N Engl J Med* 2004; **350**: 48-58 [PMID: 14702427 DOI: 10.1056/NEJMra021678]
79. **Stratton IM**, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 2000; **321**: 405-412 [PMID: 10938048 DOI: 10.1136/bmj.321.7258.405]
80. **King P**, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *Br J Clin Pharmacol* 1999; **48**: 643-648 [PMID: 10594464 DOI: 10.1046/j.1365-2125.1999.00092.x]
81. Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group. *Diabetes Care* 1987; **10**: 1-19 [PMID: 2882967 DOI: 10.2337/diacare.10.1.1]
82. Diabetes C, Complications Trial /Epidemiology of Diabetes I, Complications Study Research G. Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up. *Diabetes Care* 2016; **39**: 686-693 [PMID: 26861924 DOI: 10.2337/dc15-1990]
83. **Nathan DM**. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. *Diabetes Care* 2014; **37**: 9-16 [PMID: 24356592 DOI: 10.2337/dc13-2112]
84. **Thorn LM**, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Wadén J, Rönnback M, Rosengård-Bärlund M, Björkesten CG, Taskinen MR, Groop PH. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). *Diabetes Care* 2005; **28**: 2019-2024 [PMID: 16043748 DOI: 10.2337/diacare.28.8.2019]
85. **Chaturvedi N**, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. *Diabetes Care* 2001; **24**: 284-289 [PMID: 11213880 DOI: 10.2337/diacare.24.2.284]
86. **De Block CE**, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. *Diabetes Care* 2005; **28**: 1649-1655 [PMID: 15983315 DOI: 10.2337/diacare.28.7.1649]
87. **Anan F**, Takayuki M, Takahashi N, Nakagawa M, Eshima N, Saikawa T, Yoshimatsu H. Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. *Hypertens Res* 2009; **32**: 299-305 [PMID: 19262488 DOI: 10.1038/hr.2009.8]
88. **Bonadonna R**, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. *Diabetes Care* 2006; **29**: 2701-2707 [PMID: 17130208 DOI: 10.2337/dc06-0942]
89. **Abdul-Ghani M**, Nawaf G, Nawaf F, Itzhak B, Minuchin O, Vardi P. Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. *Isr Med Assoc J* 2006; **8**: 378-382 [PMID: 16833164]
90. **Mavrakanas T**, Frachebois C, Soualah A, Aloui F, Julier I, Bastide D. C-peptide and chronic complications in patients with type-2 diabetes and the metabolic syndrome. *Presse Med* 2009; **38**: 1399-1403 [PMID: 19419831 DOI: 10.1016/j.lpm.2009.02.023]
91. **Ahamed A**, Shantha GP, Agarwal G, Senthil N, Paunikar N, Sudhakar MK. Prevalence of microvascular complications in metabolic syndrome in comparison to type 2 diabetes mellitus. *J Indian Med Assoc* 2008; **106**: 583-54, 586, 588 [PMID: 19552085]
92. **Klein BE**, Myers CE, Howard KP, Klein R. Serum Lipids and Proliferative Diabetic Retinopathy and Macular Edema in Persons With Long-term Type 1 Diabetes Mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *JAMA Ophthalmol* 2015; **133**: 503-510 [PMID: 25502808 DOI: 10.1001/jamaophthalmol.2014.5108]
93. **Sabanayagam C**, Yip W, Ting DS, Tan G, Wong TY. Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy. *Ophthalmic Epidemiol* 2016; **23**: 209-222 [PMID: 27355693 DOI: 10.1080/09286586.2016.1193618]
94. **Das R**, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and Diabetic Macular Edema: A Systematic Review and Meta-Analysis. *Ophthalmology* 2015; **122**: 1820-1827 [PMID: 26150053 DOI: 10.1016/j.ophtha.2015.05.011]
95. **Salinero-Fort MÁ**, San Andrés-Rebollo FJ, de Burgos-Lunar C, Arrieta-Blanco FJ, Gómez-Campelo P. Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study. *PLoS One* 2013; **8**: e76417 [PMID: 24146865 DOI: 10.1371/journal.pone.0076417]
96. **Wong TY**, Cheung N, Tay WT, Wang JJ, Aung T, Saw SM, Lim SC, Tai ES, Mitchell P. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. *Ophthalmology* 2008; **115**: 1869-1875 [PMID: 18584872 DOI: 10.1016/j.ophtha.2008.05.014]
97. **Wong TY**, Klein R, Islam FM, Cotch MF, Folsom AR, Klein BE, Sharrett AR, Shea S. Diabetic retinopathy in a multi-ethnic cohort in the United States. *Am J Ophthalmol* 2006; **141**: 446-455 [PMID: 16490489 DOI: 10.1016/j.ajo.2005.08.063]
98. **Lyons TJ**, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT, Klein RL. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. *Invest Ophthalmol Vis Sci* 2004; **45**: 910-918 [PMID: 14985310 DOI: 10.1167/iovs.02-0648]
99. **Modjtahedi BS**, Bose N, Papakostas TD, Morse L, Vavvas DG, Kishan AU. Lipids and Diabetic Retinopathy. *Semin Ophthalmol* 2016; **31**: 10-18 [PMID: 26959124 DOI: 10.3109/08820538.2015.1114869]
100. **Morgan CL**, Owens DR, Aubonnet P, Carr ES, Jenkins-Jones S, Poole CD, Currie CJ. Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study. *BMJ Open* 2013; **3**: e004025 [PMID: 24302508 DOI: 10.1136/bmjopen-2013-004025]
101. **Keech A**, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005; **366**: 1849-1861 [PMID: 16310551 DOI: 10.1016/S0140-6736(05)67667-2]
102. **Sacks FM**, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernández C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. *Circulation* 2014; **129**: 999-1008 [PMID: 24352521 DOI: 10.1161/CIRCULATIONAHA.113.002529]
103. **Kim JA**, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation* 2006; **113**: 1888-1904 [PMID: 16618833 DOI: 10.1161/CIRCULATIONAHA.105.563213]
104. **Yeh PT**, Yang CM, Huang JS, Chien CT, Yang CH, Chiang YH, Shih YF. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. *Ophthalmology* 2008; **115**: 734-737.e1 [PMID: 18177940 DOI: 10.1016/j.ophtha.2007.05.041]
105. **Brownlee M**. Lilly Lecture 1993. Glycation and diabetic complications. *Diabetes* 1994; **43**: 836-841 [PMID: 8194672 DOI: 10.2337/diab.43.6.836]
106. **Kim JH**, Baik HW, Yoon YS, Joung HJ, Park JS, Park SJ, Jang EJ, Park SW, Kim SJ, Kim MJ, Jeon DO, Cho HJ, Lee SJ, Im SG, Jang SK. Measurement of antioxidant capacity using the biological antioxidant potential test and its role as a predictive marker of metabolic syndrome. *Korean J Intern Med* 2014; **29**: 31-39 [PMID: 24574831 DOI: 10.3904/kjim.2014.29.1.31]
107. **Rahimi R**, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. *Biomed Pharmacother* 2005; **59**: 365-373 [PMID: 16081237 DOI: 10.1016/j.biopha.2005.07.002]
108. **Coucha M**, Elshaer SL, Eldahshan WS, Mysona BA, El-Remessy AB. Molecular mechanisms of diabetic retinopathy: potential therapeutic targets. *Middle East Afr J Ophthalmol* 2015; **22**: 135-144 [PMID: 25949069 DOI: 10.4103/0974-9233.154386]
109. **Roy S**, Kern TS, Song B, Stuebe C. Mechanistic Insights into Pathological Changes in the Diabetic Retina: Implications for Targeting Diabetic Retinopathy. *Am J Pathol* 2017; **187**: 9-19 [PMID: 27846381 DOI: 10.1016/j.ajpath.2016.08.022]
110. **Fowler MJ**. Microvascular and Macrovascular Complications of Diabetes. *Clinical Diabetes* 2008: 77 [DOI: 10.2337/diaclin.26.2.77]
111. **Antonetti DA**, Klein R, Gardner TW. Diabetic retinopathy. *N Engl J Med* 2012; **366**: 1227-1239 [PMID: 22455417 DOI: 10.1056/NEJMra1005073]
112. **Coelho M**, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. *Arch Med Sci* 2013; **9**: 191-200 [PMID: 23671428 DOI: 10.5114/aoms.2013.33181]
113. **Berg AH**, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. *Circ Res* 2005; **96**: 939-949 [PMID: 15890981 DOI: 10.1161/01.RES.0000163635.62927.34]
114. **Ryo M**, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. *Circ J* 2004; **68**: 975-981 [PMID: 15502375 DOI: 10.1253/circj.68.975]
115. **Steppan CM**, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. *Nature* 2001; **409**: 307-312 [PMID: 11201732 DOI: 10.1038/35053000]
116. **Steppan CM**, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin. *Mol Cell Biol* 2005; **25**: 1569-1575 [PMID: 15684405 DOI: 10.1128/MCB.25.4.1569-1575.2005]
117. **Zaidi SI**, Shirwany TA. RELATIONSHIP OF SERUM RESISTIN WITH INSULIN RESISTANCE AND OBESITY. *J Ayub Med Coll Abbottabad* 2015; **27**: 552-555 [PMID: 26721005]
118. **Azab N**, Abdel-Aziz T, Ahmed A, El-deen IM. Correlation of serum resistin level with insulin resistance and severity of retinopathy in type 2 diabetes mellitus. Journal of Saudi Chemical Society. 2016: 272 [DOI: 10.1016/j.jscs.2012.07.003]
119. **Tokuyama Y**, Osawa H, Ishizuka T, Onuma H, Matsui K, Egashira T, Makino H, Kanatsuka A. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. *Metabolism* 2007; **56**: 693-698 [PMID: 17445546 DOI: 10.1016/j.metabol.2006.12.019]
120. **Rosen ED**, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. *Nature* 2006; **444**: 847-853 [PMID: 17167472 DOI: 10.1038/nature05483]
121. **Kalderon B**, Mayorek N, Berry E, Zevit N, Bar-Tana J. Fatty acid cycling in the fasting rat. *Am J Physiol Endocrinol Metab* 2000; **279**: E221-E227 [PMID: 10893343]
122. **Santomauro AT**, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. *Diabetes* 1999; **48**: 1836-1841 [PMID: 10480616 DOI: 10.2337/diabetes.48.9.1836]
123. **Shen J**, Bi YL, Das UN. Potential role of polyunsaturated fatty acids in diabetic retinopathy. *Arch Med Sci* 2014; **10**: 1167-1174 [PMID: 25624855 DOI: 10.5114/aoms.2014.47826]
124. **Savini I**, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: strategies finalized to improve redox state. *Int J Mol Sci* 2013; **14**: 10497-10538 [PMID: 23698776 DOI: 10.3390/ijms140510497]
125. **Vendrell J**, Chacón MR. TWEAK: A New Player in Obesity and Diabetes. *Front Immunol* 2013; **4**: 488 [PMID: 24416031 DOI: 10.3389/fimmu.2013.00488]
126. **Coppack SW**. Pro-inflammatory cytokines and adipose tissue. *Proc Nutr Soc* 2001; **60**: 349-356 [PMID: 11681809 DOI: 10.1079/PNS2001110]
127. **Kowluru RA**, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy. *Br J Ophthalmol* 2004; **88**: 1343-1347 [PMID: 15377563 DOI: 10.1136/bjo.2003.038133]
128. **El-Asrar AM**. Role of inflammation in the pathogenesis of diabetic retinopathy. *Middle East Afr J Ophthalmol* 2012; **19**: 70-74 [PMID: 22346117 DOI: 10.4103/0974-9233.92118]
129. **Liu Y**, Biarnés Costa M, Gerhardinger C. IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation. *PLoS One* 2012; **7**: e36949 [PMID: 22615852 DOI: 10.1371/journal.pone.0036949]
130. **Lyons CL**, Kennedy EB, Roche HM. Metabolic Inflammation-Differential Modulation by Dietary Constituents. *Nutrients* 2016; **8**: pii: E247 [PMID: 27128935 DOI: 10.3390/nu8050247]
131. **Behl T**, Kaur I, Kotwani A. Role of leukotrienes in diabetic retinopathy. *Prostaglandins Other Lipid Mediat* 2016; **122**: 1-9 [PMID: 26673555 DOI: 10.1016/j.prostaglandins.2015.12.001]
132. **El-Asrar AM**, Missotten L, Geboes K. Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes. *Br J Ophthalmol* 2008; **92**: 1534-1539 [PMID: 18952655 DOI: 10.1136/bjo.2008.142182]
133. **Du Y**, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. *Am J Physiol Regul Integr Comp Physiol* 2004; **287**: R735-R741 [PMID: 15371279 DOI: 10.1152/ajpregu.00080.2003]
134. **Ayalasomayajula SP**, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. *Eur J Pharmacol* 2003; **458**: 283-289 [PMID: 12504784 DOI: 10.1016/S0014-2999(02)02793-0]
135. **Zhuang W**, Wang G, Li L, Lin G, Deng Z. Omega-3 polyunsaturated fatty acids reduce vascular endothelial growth factor production and suppress endothelial wound repair. *J Cardiovasc Transl Res* 2013; **6**: 287-293 [PMID: 22993129 DOI: 10.1007/s12265-012-9409-0]
136. National Institutes of Health NHLaBI. ATP III Guidelines At-A-Glance: Quick Desk Reference. In: Services UDoHaH, editor. National Cholesterol Education Program: Public Health Service; 2001

**P-Reviewer:** Tarantino G, Raghow RS, Riutta AA, Malfitano C **S-Editor:** Kong JX

**L-Editor: E-Editor:**

**Specialty type:** Endocrinology and metabolism

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C, C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Schematic presentation of the postulated primary role of hyperglycemia and insulin deficiency in driving diabetic microvascular complications in type-1 diabetes.** Secondary mediators of retinal vascular damage include oxidative stress, inflammation and leukostasis.



**Figure 2 Schematic presentation of the multiple pathways involved in metabolic syndrome including hypertension, central obesity, dyslipidemia, adipose tissue and adipokine’s dysfunction, altered free fatty acids levels and polyunsaturated fatty acid metabolism leading to local and systemic inflammation.** FFA: Free fatty acids; PUFA: Polyunsaturated fatty acid.



**Figure 3 Schematic presentation of the postulated multifactorial and interrelated pathways of insulin resistance, inflammation, dyslipidemia and hyperglycemia that collectively drive microvascular complications in patients with metabolic syndrome with and without established history of diabetes.**

**Table 1 Adult treatment panel III criteria for diagnosis of the metabolic syndrome1**

|  |
| --- |
| **≥ 3 of the following** |
| Fasting glucose | ≥ 6.1 mmol/L (110 mg/dL) |
| HDL cholesterol | Male: < 1.0 mmol/L (40 mg/dL)Female: < 1.3 mmol/L (50 mg/dL) |
| Triglycerides | ≥ 1.7 mmol/L (150 mg/dL) |
| Abdominal obesity | Male waist circumference: ≥ 102 cmFemale waist circumference: ≥ 88 cm |
| Blood pressure | ≥ 130/85 mmHg |

1http://www.nhlbi.nih.gov/files/docs/guidelines/atglance.pdf (acquired 2016 Jul 17[136]).